Fixed-Dose Netarsudil/Latanoprost Versus Artificial Tears in Pseudophakic Bullous Keratopathy with Glaucoma: A Randomized Trial

Background and Objectives: Evidence for fixed-dose netarsudil/latanoprost in pseudophakic bullous keratopathy (PBK) with glaucoma is limited. The fixed-combination design cannot separate the effect of netarsudil from that of latanoprost, nor attribute any effect specifically to Rho-associated coiled-coil kinase (ROCK) inhibition. Materials and Methods: Fifty eyes of 50 participants with grade 1 or 2 PBK and primary open-angle glaucoma were randomized in a single-center, double-masked trial to netarsudil 0.02%/latanoprost 0.005% or preservative-free artificial tears for 12 weeks (25/group). Best-corrected visual acuity (BCVA; primary) and central corneal thickness (CCT; secondary) were analyzed using intention-to-treat mixed-effects models. Registration NCT06960629 preceded first consent; registry discrepancies are disclosed. Results: All participants completed follow-up. One active-arm baseline CCT was missing; CCT models retained available observations from all 50 participants, whereas change-based CCT analyses included 24 active and 25 control eyes. Week-12 between-group differences in change were −0.21 logMAR (95% CI −0.28 to −0.14) and −21.0 µm (95% CI −28.4 to −13.6). Interaction p values were <0.001; CCT inference was exploratory without multiplicity adjustment. In a post hoc intraocular pressure (IOP) analysis, the week-12 difference in change was −0.96 mmHg (95% CI −1.53 to −0.39; interaction p = 0.006). Hyperemia occurred in 20/25 treated eyes and reticular epithelial edema in 2/25; no serious adverse events or discontinuations were reported. Conclusions: The combination was associated with short-term BCVA improvement and modest corneal thinning. Potential functional unmasking, the unmatched control formulation, and the combination design limit interpretation. These findings are insufficient to recommend routine off-label use for PBK edema or change clinical practice.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-20
DOI
https://doi.org/10.3390/medicina62112288
Primary Topic
Corneal surgery and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fixed-Dose Netarsudil/Latanoprost Versus Artificial Tears in Pseudophakic Bullous Keratopathy with Glaucoma: A Randomized Trial

Josip Pavan, Anđela Jukić, Kata Čulina, Dubravka Biuk et al.
1 links
Medicina
Corneal surgery and disorders
article

Fixed-Dose Netarsudil/Latanoprost Versus Artificial Tears in Pseudophakic Bullous Keratopathy with Glaucoma: A Randomized Trial

Josip Pavan, Anđela Jukić, Kata Čulina, Dubravka Biuk, Anela Bečić Turkanović, Vedran Markušić, Miro Kalauz, Sanja Masnec
article en

Abstract

Background and Objectives: Evidence for fixed-dose netarsudil/latanoprost in pseudophakic bullous keratopathy (PBK) with glaucoma is limited. The fixed-combination design cannot separate the effect of netarsudil from that of latanoprost, nor attribute any effect specifically to Rho-associated coiled-coil kinase (ROCK) inhibition. Materials and Methods: Fifty eyes of 50 participants with grade 1 or 2 PBK and primary open-angle glaucoma were randomized in a single-center, double-masked trial to netarsudil 0.02%/latanoprost 0.005% or preservative-free artificial tears for 12 weeks (25/group). Best-corrected visual acuity (BCVA; primary) and central corneal thickness (CCT; secondary) were analyzed using intention-to-treat mixed-effects models. Registration NCT06960629 preceded first consent; registry discrepancies are disclosed. Results: All participants completed follow-up. One active-arm baseline CCT was missing; CCT models retained available observations from all 50 participants, whereas change-based CCT analyses included 24 active and 25 control eyes. Week-12 between-group differences in change were −0.21 logMAR (95% CI −0.28 to −0.14) and −21.0 µm (95% CI −28.4 to −13.6). Interaction p values were <0.001; CCT inference was exploratory without multiplicity adjustment. In a post hoc intraocular pressure (IOP) analysis, the week-12 difference in change was −0.96 mmHg (95% CI −1.53 to −0.39; interaction p = 0.006). Hyperemia occurred in 20/25 treated eyes and reticular epithelial edema in 2/25; no serious adverse events or discontinuations were reported. Conclusions: The combination was associated with short-term BCVA improvement and modest corneal thinning. Potential functional unmasking, the unmatched control formulation, and the combination design limit interpretation. These findings are insufficient to recommend routine off-label use for PBK edema or change clinical practice.

MedicinaVol. 62(11)
University Hospital Centre Zagreb (HR), University of Zagreb (HR), University Hospital Dubrava (HR), University Clinical Centre Maribor (SI), Klinički bolnički centar Osijek (HR), University of Osijek (HR)
Good health and well-being
Corneal surgery and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon